Scientists View Bone Marrow Xenotransplant With Optimism, Caution

Optimism, Caution Date: March 4, 1996 (The Scientist, Vol:10, #5, pg.3 & 6, March 4, 1996) (Copyright ©, The Scientist, Inc.) When Oakland, Calif., AIDS activist-now patient-turned-guinea-pig-Jeff Getty received baboon bone marrow cells in December, doctors gave the daring cross-species experiment little chance of working. Now, three months later, scientists are debating not only whether or not the procedure was a success, but also if it was appropriate in the first place. In question also

Written bySteven Benowitz
| 10 min read

Register for free to listen to this article
Listen with Speechify
0:00
10:00
Share

Optimism, Caution Date: March 4, 1996
(The Scientist, Vol:10, #5, pg.3 & 6, March 4, 1996)
(Copyright ©, The Scientist, Inc.)

When Oakland, Calif., AIDS activist-now patient-turned-guinea-pig-Jeff Getty received baboon bone marrow cells in December, doctors gave the daring cross-species experiment little chance of working. Now, three months later, scientists are debating not only whether or not the procedure was a success, but also if it was appropriate in the first place. In question also is what the Food and Drug Administration (FDA), which approved the procedure, should do next.

UNDAUNTED: University of Pittsburgh researcher Suzanne T. Iidstad plans to apply for FDA permission to perform another baboon transplant. To date, there are few signs that the baboon marrow cells transplanted into the bone marrow of the 38-year-old Getty, who was dying of AIDS, have "engrafted," or taken hold in his immune system. Because baboons are resistant to HIV, doctors ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies